Schulz-Utermoehl T, Bennett AJ, Ellis SW, Tucker GT, Boobis AR, Edwards RJ (1999) Polymor-
phic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression.
Pharmacogenetics 9:357–366
Short CE, Paddleford RR (1973) Letter: malignant hyperthermia in the dog. Anesthesiology
39:462–463
Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH (2003)
Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes
p450. Drug Metab Dispos 31:1161–1169
Sim E, Walters K, Boukouvala S (2008) Arylamine N-acetyltransferases: from structure to
function. Drug Metab Rev 40:479–510
Simanainen U, Tuomisto JT, Tuomisto J, Viluksela M (2003) Dose-response analysis of short-
term effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in three differentially susceptible rat
lines. Toxicol Appl Pharmacol 187:128–136
Stampfli HF, Quon CY (1995) Polymorphic metabolism of flestolol and other ester-containing
compounds by a carboxylesterase in New Zealand white rabbit blood and cornea. Res Commun
Mol Pathol Pharmacol 88:87–97
Stewart SL, Hogan K, Rosenberg H, Fletcher JE (2001) Identification of the Arg1086His mutation
in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North
American family with malignant hyperthermia. Clin Genet 59:178–184
Sugamori KS, Brenneman D, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, Grant DM
(2007) Effect of arylamine acetyltransferaseNat3gene knockout onN-acetylation in the
mouse. Drug Metab Dispos 35:1064–1070
Tasaki T, Iwata H, Kazusaka A, Fujita S (1998) Regio- and stereoselectivity in propranolol metabo-
lism by dog liver microsomes and the expressed dog CYP2D15. J Biochem 123:747–751
Tenmizu D, Endo Y, Noguchi K, Kamimura H (2004) Identification of the novel canine CYP1A2
1117 C>T SNP causing protein deletion. Xenobiotica 34:835–846
Tenmizu D, Noguchi K, Kamimura H (2006a) Elucidation of the effects of the CYP1A2 deficiency
polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2, 3-d] pyrimidine-
2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.
Drug Metab Dispos 34:1811–1816
Tenmizu D, Noguchi K, Kamimura H, Ohtani H, Sawada Y (2006b) The canine CYP1A2
deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-
7-methylpyrido[2, 3-d]pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhib-
itor. Drug Metab Dispos 34:800–806
Tobin T, Blake JW, Tai CY, Sturma L, Arnett S (1976) Pharmacology of procaine in horse:
Procaine esterase properties of equine plasma and synovial-fluid. Am J Vet Res 37:1165–1170
Tranquilli WJ, Paul AJ, Seward RL (1989) Ivermectin plasma concentrations in collies sensitive to
ivermectin-induced toxicosis. Am J Vet Res 50:769–770
Trepanier LA, Ray K, Winand NJ, Spielberg SP, Cribb AE (1997) Cytosolic arylamine
N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence ofNAT
genes. Biochem Pharmacol 54:73–80
Trepanier LA, Cribb AE, Spielberg SP, Ray K (1998) Deficiency of cytosolic arylamine
N-acetylation in the domestic cat and wild felids caused by the presence of a singleNAT1-
like gene. Pharmacogenetics 8:169–179
Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, Beare CM (1997)
Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a
restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88–94
Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, Yoshida I, Kimura A, Sakisaka S,
Adachi Y, Kuwano M (1998) Mutations in the canilicular multispecific organic anion transporter
(cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson
syndrome. Hum Mol Genet 7:203–207
Waldron-Mease E, Klein LV, Rosenberg H, Leitch M (1981) Malignant hyperthermia in a
halothane-anesthetized horse. J Am Vet Med Assoc 179:896–898
76 C.M. Mosher and M.H. Court